Alec Stranahan
Stock Analyst at B of A Securities
(0.61)
# 4,065
Out of 5,182 analysts
34
Total ratings
37.04%
Success rate
-60.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Buy | $38 → $21 | $7.58 | +177.04% | 1 | Mar 27, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $288 → $318 | $276.50 | +15.01% | 6 | Jan 22, 2026 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $7.22 | -3.05% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $12.80 | -6.25% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $21.71 | -95.39% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $8.67 | -19.26% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $31.19 | +34.66% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $21.48 | +16.39% | 5 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $2.29 | +380.35% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $4.55 | +31.87% | 2 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $13 → $15 | $3.57 | +320.17% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $146.23 | -62.39% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $36.96 | -83.77% | 2 | Dec 29, 2022 |
Wave Life Sciences
Mar 27, 2026
Maintains: Buy
Price Target: $38 → $21
Current: $7.58
Upside: +177.04%
Krystal Biotech
Jan 22, 2026
Maintains: Buy
Price Target: $288 → $318
Current: $276.50
Upside: +15.01%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $7.22
Upside: -3.05%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $12.80
Upside: -6.25%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $21.71
Upside: -95.39%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $8.67
Upside: -19.26%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $31.19
Upside: +34.66%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $21.48
Upside: +16.39%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $2.29
Upside: +380.35%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $4.55
Upside: +31.87%
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $3.57
Upside: +320.17%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $146.23
Upside: -62.39%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $36.96
Upside: -83.77%